<DOC>
	<DOCNO>NCT00963248</DOCNO>
	<brief_summary>Question : In stage EBV-infection selective reduction immunosuppressive medication reasonable minimize risk PTLD , without put transplant recipient risk acute rejection episode due immunosuppression ? Aim study : Identification patient high-risk PTLD .</brief_summary>
	<brief_title>EBV Infection Risk Factor PTLD Pediatric Adult Renal Transplant Recipients</brief_title>
	<detailed_description>PTLD represent heterogeneous group abnormal lymphoid proliferation , generally B-cells , occur set ineffective T-cell function pharmacological immunosuppression . Because vast majority PTLDs associate Epstein-Barr virus ( EBV ) infection , surveillance EBV infection may potential prevent development PTLD early intervention . However , cut-off value `` high '' EBV viral load remain badly define due lack prospective study assay standardization . The aim ongoing multicenter prospective study serial detection primary EBV infection reactivation homogeneous patient population pediatric renal transplant recipient first 2 year posttransplant combine analysis quantitative EBV viral load standardize quantitative PCR technique , EBV serology EBV-specific T-lymphocytes identification high-risk patient .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Epstein-Barr Virus Infections</mesh_term>
	<criteria>male female pediatric adult renal transplant recipient write informed consent psychological illness allow patient understand study participate follow free write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>EBV</keyword>
	<keyword>PTLD</keyword>
	<keyword>RTx</keyword>
	<keyword>pediatric</keyword>
</DOC>